ROBINS HARLAN S sold $1.8M of ADPT

ROBINS HARLAN S (Chief Scientific Officer) sold 106,160 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $17.41 ($17.37–$18.01, $1.85M total) across 2 trades over 2026-06-15 to 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROBINS HARLAN S
Published Jun 18, 2026, 12:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 12:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
medium confidence
Mentioned
$ADPT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price range, and that it was executed under a Rule 10b5-1 plan by the Chief Scientific Officer.

02

Market read

This provides a concrete insider liquidity datapoint but no new fundamental catalyst for ADPT.

03

What to watch

Traders may over-weight insider sales; without accompanying buys, guidance, trial updates, or financing news, the filing is unlikely to change valuation assumptions.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-17; trades executed 2026-06-15 to 2026-06-16.

Background

The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).

Company-level read

Ticker impact

$ADPTNeutralMedium confidence
Context

SEC Form 4 shows CSO Robins Harlan S sold 106,160 ADPT shares in open-market trades for ~$1.85M under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any reaction would be modest and sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a primary-source insider transaction with defined parameters (10b5-1, open-market, weighted avg ~$17.41). The article provides no new operational/financial catalyst, so impact should be constrained.

Market effects

No sector-level read-across; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • Adaptive Biotechnologies Corp

    Subject of the Form 4 insider sale disclosure.

  • ROBINS HARLAN S

    Chief Scientific Officer who sold 106,160 shares in open-market trades under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.